Tislelizumab plus bevacizumab and XELOX as first-line treatment of MSS/pMMR RAS-mutant metastatic colorectal cancer (TACTIC CRC-02): a phase II study
First-line treatment with tislelizumab plus XELOX and bevacizumab demonstrated a high ORR and a manageable safety profile in patients with MSS/pMMR, RAS-mutant mCRC. This chemo-immunotherapy combination represents a promising strategy and warrants further investigation in a phase III trial.
Authors
- W. Yang
- X. Liu
- Z. Jiang
- L. Zhang
- B. Cao
- J. Lu
- K. Ou
- X. Ma
- H. Zhang
- W. Zhang
- Q. Wang
- L. Yang
- A. Zhou
- L. Gao
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
- National Cancer Center (US)
- Cancer Hospital of Huanxing Chaoyang District Beijing (CN)
Publication Details
- Journal
- ESMO Open
- Published
- 2026-01-28
- DOI
- https://doi.org/10.1016/j.esmoop.2025.106056
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Chinese Academy of Medical Sciences